Literature DB >> 34221161

Modifiable Risk Factors and Atrial Fibrillation: the Quest for a Personalized Approach.

Lavinia-Lucia Matei1, Calin Siliste1, Dragos Vinereanu1.   

Abstract

Background:Atrial fibrillation (AF) is the most common tachyarrhythmia, affecting up to 4% of the general population. Susceptibility to AF episodes can be explained by various risk factors (RF) that alter the substrate of the left atrium. Association between several RF and AF development and recurrence has been demonstrated in several studies. Areas of uncertainty: Treatment strategies depend on patients' characteristics and comorbidities. Medical literature and consensus documents recommend an integrated approach, but also identify evidence gaps in treating patients with severe comorbidities. Data sources: Literature search was performed using PubMed electronic database. We used the following terms as key words: atrial fibrillation, risk factors, comorbidities, primary prevention, secondary prevention.
Results: Active intervention helps control the burden of AF and increase the chances of a positive outcome on the long term. Aggressive control and individualized treatment of most prevalent modifiable risk factors can reduce the risk of atrial fibrillation. Optimization of treatment strategy should be performed periodically, since RF and comorbidities are dynamic and often evolve.
Conclusion: Personalized strategies should be applied to each patient after careful assessment of individual risk. A personalized approach is indicated to both reduce the burden of AF and improve symptoms, quality of life and survival. Close attention to details is required to avoid disease and therapy related complications in the presence of comorbidities.

Entities:  

Year:  2021        PMID: 34221161      PMCID: PMC8224718          DOI: 10.26574/maedica.2020.16.1.88

Source DB:  PubMed          Journal:  Maedica (Bucur)        ISSN: 1841-9038


  97 in total

1.  Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.

Authors:  Bernhard Richter; Michael Derntl; Manfred Marx; Peter Lercher; Heinz D Gössinger
Journal:  Am Heart J       Date:  2007-01       Impact factor: 4.749

2.  Pulmonary vein isolation with concomitant renal artery denervation is associated with reduction in both arterial blood pressure and atrial fibrillation burden: Data from implantable cardiac monitor.

Authors:  Alexander Romanov; Evgeny Pokushalov; Dmitry Ponomarev; Artem Strelnikov; Vitaliy Shabanov; Denis Losik; Alexander Karaskov; Jonathan S Steinberg
Journal:  Cardiovasc Ther       Date:  2017-08       Impact factor: 3.023

3.  Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.

Authors:  Peter M Okin; Kristian Wachtell; Richard B Devereux; Katherine E Harris; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Lars H Lindholm; Markku S Nieminen; Jonathan M Edelman; Darcy A Hille; Björn Dahlöf
Journal:  JAMA       Date:  2006-09-13       Impact factor: 56.272

4.  Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.

Authors:  Andreas Goette; Norbert Schön; Paulus Kirchhof; Günter Breithardt; Thomas Fetsch; Karl Georg Häusler; Helmut U Klein; Gerhard Steinbeck; Karl Wegscheider; Thomas Meinertz
Journal:  Circ Arrhythm Electrophysiol       Date:  2011-12-07

5.  Pulse pressure and risk of new-onset atrial fibrillation.

Authors:  Gary F Mitchell; Ramachandran S Vasan; Michelle J Keyes; Helen Parise; Thomas J Wang; Martin G Larson; Ralph B D'Agostino; William B Kannel; Daniel Levy; Emelia J Benjamin
Journal:  JAMA       Date:  2007-02-21       Impact factor: 56.272

6.  Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

Authors:  L Julian Haywood; Charles E Ford; Richard S Crow; Barry R Davis; Barry M Massie; Paula T Einhorn; Angela Williard
Journal:  J Am Coll Cardiol       Date:  2009-11-24       Impact factor: 24.094

Review 7.  Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target.

Authors:  Jeff S Healey; Stuart J Connolly
Journal:  Am J Cardiol       Date:  2003-05-22       Impact factor: 2.778

8.  Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

Authors:  Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

9.  Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.

Authors:  Roland E Schmieder; Sverre E Kjeldsen; Stevo Julius; Gordon T McInnes; Alberto Zanchetti; Tsushung A Hua
Journal:  J Hypertens       Date:  2008-03       Impact factor: 4.844

Review 10.  Radiofrequency Ablation versus Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation: A Meta-Analysis.

Authors:  Ali H Hachem; Joseph E Marine; Housam A Tahboub; Sana Kamdar; Shaffi Kanjwal; Ronak Soni; Khalil Kanjwal
Journal:  Cardiol Res Pract       Date:  2018-04-01       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.